MONDAY, Sept. 9, 2024 -- Women with hepatocellular carcinoma (HCC) are less likely to receive a deceased-donor liver transplant (DDLT) and more...
Vous n'êtes pas connecté
FRIDAY, Aug. 16, 2024 -- For patients with hepatocellular carcinoma (HCC), immune checkpoint inhibitor (ICI) use prior to liver transplant (LT) does not worsen outcomes, according to research published online July 10 in the Journal of...
MONDAY, Sept. 9, 2024 -- Women with hepatocellular carcinoma (HCC) are less likely to receive a deceased-donor liver transplant (DDLT) and more...
TUESDAY, Sept. 10, 2024 -- For adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve...
THURSDAY, Aug. 29, 2024 -- In patients with abdominal pain and gallstones, a more restrictive approach may avoid unnecessary cholecystectomies, with...
While immune checkpoint inhibitors (ICIs) can provide lifesaving treatment for patients with cancer, they have also been found to cause immune-related...
Empagliflozin, an SGLT2 inhibitor, is proven safe and effective for heart attack patients, offering a new treatment option to improve outcomes.
A new tool for monitoring immune health patterns over time has revealed how a pair of checkpoint inhibitor therapies works together to recruit new...
Many individuals worldwide suffer from chronic liver disease (CLD), which poses significant concerns for its tendency to lead to hepatocellular...
WEDNESDAY, Sept. 4, 2024 -- Higher suicide deaths are seen among cancer patients who do not undergo recommended surgery, according to a research...
While immune checkpoint inhibitors (ICIs) can provide lifesaving treatment for patients with cancer, they have also been found to cause immune-related...
A new tool for monitoring immune health patterns over time has revealed how a pair of checkpoint inhibitor therapies work together to recruit new...